Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M108 plus CAPOX in First-line CLDN18.2+ Gastric/GEJ Cancer
NCT06177041Phase 3Recruiting
- Sponsor
- Beijing Mingzhi Zhishan Biotechnology
- Start
- Dec 2023
- Primary completion
- Jan 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing M108 + CAPOX with Placebo + CAPOX (2 arms). Primary endpoint: Progression Free Survival at 24 months. Started Dec 2023; status: recruiting.
02
Drugs
M108
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06177041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06177041.